Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of petosemtamab versus investigator's choice monotherapy in previously treated recurrent or metastatic head and neck squamous cell carcinoma
2023-510322-32-00Phase 3Authorised
- Sponsor
- Genmab
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Genmab. Primary endpoint: Overall survival. Planned start Aug 2024; status: authorised.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-510322-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510322-32-00.